奥田 武司(オクダ タケシ)
医学科 | 講師 |
Last Updated :2024/11/09
■教員コメント
コメント
脳腫瘍領域全般と、神経内視鏡手術についてコメント可能です。
報道関連出演・掲載一覧
<報道関連出演・掲載一覧>
●2019/10/8
朝日放送「キャスト」
米倉涼子さんの「低髄液圧症候群」について
●2019/7/21
サンケイスポーツ
三遊亭円楽さんの脳腫瘍について
■研究者基本情報
J-Global ID
研究キーワード
- VGEF MET 手術トレーニング 神経内視鏡手術 下垂体腫瘍 転移性脳腫瘍 EGFR 癌 神経膠腫 病理学 ミクログリア DNAマイクロアレイ インターフェロン 免疫学 脳、神経 神経膠芽腫
現在の研究分野(キーワード)
脳腫瘍領域全般と、神経内視鏡手術についてコメント可能です。
■経歴
委員歴
■研究活動情報
論文
- Juli Yamashita; Takeshi Okuda; Takayuki Tasaki; Jun C TakahashiNeurologia medico-chirurgica 2024年09月Endoscopic surgery, including endoscopic endonasal transsphenoidal surgery (ETSS), requires special psychomotor skills from surgeons. The learning curve in the acquisition of psychomotor skills varies among individuals, and studies about laparoscopy indicate that the difference can be predicted using spatial ability tests. We examined the association between the results of such tests and the learning curve in ETSS to determine the need for a personalized curriculum for ETSS skill training. A total of 30 fifth-year medical students from Kindai University School of Medicine (17 men, 13 women; mean age, 26 years) without ETSS experience completed the spatial orientation test (SOT) for the measurement of spatial visualization ability. They performed the dural incision task (DIT) twice on an ETSS training model for surgical psychomotor skill evaluation. The SOT scores (angle errors) exhibited substantial individual differences in spatial visualization ability, whereas the DIT scores significantly improved in the second trial (Wilcoxon signed-rank test, P = 0.0035). However, no significant difference was observed in the DIT scores between the smaller error and larger error groups of the SOT. The results indicated that two DIT trials were sufficient to acquire psychomotor skills for the DIT as the endoscope was almost fixed and learning only one viewpoint and line of sight combination was adequate. In conclusion, a personalized ETSS training program based on the trainee's spatial ability is not necessary for the DIT. Further research is warranted to determine the effect of spatial ability on more complex tasks, such as suturing in cranial base repair.
- HIROMASA YOSHIOKA; TAKESHI OKUDA; MITSUGU FUJITA; TAKAYUKI NAKAO; JUN C. TAKAHASHIAnticancer Research 44 8 3663 - 3667 2024年07月 [査読有り]
- 高齢発症てんかんに対する調査票を用いた スクリーニング効果の検証吉岡宏真; 奥田武司; 中岡良介; 藤田; 貢 髙橋 淳GERIATRIC NEUROSURGERY 35 59 - 63 日本老年脳神経外科学会 2023年06月 [査読有り][招待有り]
- 吉岡宏真; 奥田武司; 内山卓也; 髙橋 淳臨床検査 67 5 490 - 494 (株)医学書院 2023年05月 [査読有り][招待有り]
<文献概要>Point ●脳室とは,脳脊髄液(CSF)で満たされた脳内の空間のことである.左右一対の側脳室と正中に第三脳室・第四脳室が1つずつ存在し,合計計4つの脳室から成る.これらは相互に連絡があり,頭蓋内・脊髄腔内のくも膜下腔へと交通することで,CSFは脳室内,脳内,脊髄腔内を循環している.●CSFは主に脳内から排出される間質液から生成され,一部は脈絡叢から生成される.脈絡叢から生成されるCSFは人間の恒常性(ホメオスタシス)の維持の重要な役割を担っている.●CSFの産生と吸収機構の概念は100年間変わることがなかったが,2010年代に入って大きく変化し,新たな概念へと革新された.●新たな概念とは,脈絡叢や脳細胞から産生される間質液がCSFとなり,脳室とくも膜下腔に排出されるCSF,くも膜顆粒を介して静脈洞から吸収される経路だけではなく,硬膜リンパ管からも吸収されるということである. - Hiromasa Yoshioka; Takeshi Okuda; Takayuki Nakao; Mitsugu Fujita; Jun C TakahashiAnticancer research 42 8 4173 - 4178 2022年08月 [査読有り]
BACKGROUND/AIM: Standard treatment options for primary central nervous system lymphoma (PCNSL) include high-dose methotrexate (HD-MTX)-based drug therapy and whole-brain radiation therapy. However, there are many cases in which these standard treatment options are not tolerated for various reasons. In the present study, five cases of refractory/relapsed PCNSL that are difficult to treat with standard treatment were successfully treated by tirabrutinib. PATIENTS AND METHODS: A total of 5 patients (4 women, 1 man) with refractory (n=3) and relapsed (n=2) PCNSL were included. The patients had a median age of 76 years and a median Karnofsky performance status (KPS) of 40. The reasons why standard treatment cannot be given to these patients are the low KPS, renal dysfunction, and resistance to HD-MTX. Administration of a drug via the oral route was challenging in three patients; thus, these patients were administered tirabrutinib in suspension through a nasogastric tube. RESULTS: Imaging findings showed that the patients achieved a 100% response rate to tirabrutinib, with a median survival of 8 months. As symptoms improved, 2 of the 3 patients who were initially administered tirabrutinib via a nasogastric tube were able to receive the drug via the oral route. Three patients developed adverse reactions; however, treatment was not interrupted because they were manageable. CONCLUSION: Tirabrutinib was effective in the treatment of patients who were unable to receive standard treatment options. Tirabrutinib may be considered one of the novel treatment strategies that could improve the prognosis of PCNSL patients in the future. - Hayato Kaida; Takeshi Okuda; Kohei Hanaoka; Kazunari IshiiClinical nuclear medicine 47 11 965 - 967 2022年06月ABSTRACT: A 20-year-old man had left visual impairment and homonymous hemianopsia. MRI findings suggested enlargement of an optic glioma, because optic glioma was indicated by MRI 14 years earlier without a definite pathological diagnosis. 11C-methionine (MET) PET showed high uptake in the tumor in the parasellar region. Transnasal endoscopic biopsy was performed, and an inflammatory pseudotumor (IPT) was diagnosed based on histopathological findings. High MET uptake in a parasellar IPT has apparently not been previously reported. Clinicians should be aware of the possibility of high MET uptake in IPT, because this image could provide an interpretation pitfall.
- 小脳出血にて発症した肺血管肉腫原発の転移性脳腫瘍の1例濱田 有深; 奥田 武司; 西川 裕作; 中尾 剛幸; 田崎 貴之; 吉岡 宏真; 清水 重喜; 高橋 淳脳神経外科速報 32 2 e8 - e15 (株)メディカ出版 2022年03月 [査読有り]
30代男性。咳嗽・胸痛・血痰を主訴に近医を受診し、胸部X線で両側肺野に瀰漫性スリガラス状陰影を認められ、当院に紹介された。胸部CTでスリガラス状陰影に加えて多発する結節影を認め、悪性疾患の鑑別のため気管支鏡検査目的に入院となった。気管支鏡で瀰漫性の出血所見を認め、左上葉の結節から生検を行ったが確定診断は得られなかった。悪性疾患等の鑑別が必要であるため胸腔鏡下肺部分切除術を施行し、術中・術後に合併症は認めなかったが、術後3日目に突然の頭痛・嘔吐が出現し、頭部CTで小脳出血を認めた。脳血管病変の精査のためCT angiographyを施行し、明らかな血管異常は認めなかったが、血腫が拡大したため緊急で開頭血腫除去術を施行した。血腫を吸引で除去したところ腫瘍性病変を認めたため、この病巣を摘出して病理組織学的検査を行い、血管肉腫と診断した。肺病変の病理組織学的診断も同様であり、肺血管肉腫原発の転移性脳腫瘍と診断した。 - 奥田 武司Brain Nursing 38 1 70 - 71 (株)メディカ出版 2022年01月
- 奥田 武司Brain Nursing 38 1 76 - 79 (株)メディカ出版 2022年01月
- Hiromasa Yoshioka; Takeshi Okuda; Takayuki Nakao; Mitsugu Fujita; Jun C TakahashiAnticancer research 41 8 4169 - 4172 2021年08月 [査読有り]
BACKGROUND/AIM: Leptomeningeal carcinomatosis (LMC) with hydrocephalus is particularly difficult to treat, and its prognosis is extremely poor. The therapeutic outcomes of 14 patients with LMC-associated hydrocephalus who were treated with cerebrospinal fluid shunting are reported. PATIENTS AND METHODS: The study subjects were 14 LMC patients with solid primary cancer who had developed hydrocephalus. RESULTS: Postoperatively, both symptoms and Karnofsky performance status improved in 100% of patients. Postoperative therapy consisted of whole-brain radiotherapy in 4 cases and molecular targeted therapy in 4, with 6 patients not receiving any postoperative treatment. Median overall survival was 3.7 months, with no significant difference between those who underwent postoperative therapy and those who did not. However, two of those who received molecular targeted therapy survived for more than one year. CONCLUSION: Cerebrospinal fluid shunting for LMC-associated hydrocephalus is an effective therapeutic procedure from the palliative viewpoint. Patients for whom molecular targeted therapy is indicated may have better long-term survival. - Hiromasa Yoshioka; Takeshi Okuda; Takayuki Nakao; Mitsugu Fujita; Jun C. TakahashiInternational Cancer Conference Journal 10 4 290 - 293 2021年06月 [査読有り]
We report that tirabrutinib was administered via nasogastric tubes to treat an elderly patient with primary central nervous system lymphoma (PCNSL). The patient was a 76-year-old woman who underwent endoscopic biopsy of multiple intracerebral masses, which resulted in the diagnosis of diffuse large B-cell lymphoma. The patient was diagnosed with PCNSL and was started on an induction regimen of systemic chemotherapy with rituximab in combination with high-dose methotrexate. However, after the second cycle of chemotherapy, the tumor grew rapidly, and the patient went into a coma. As a result, the treatment was changed to nasogastric tube administration of tirabrutinib suspension. After 1 week of tirabrutinib administration, the patient's level of consciousness improved, and furthermore, after 2 weeks of tirabrutinib administration, the patient was able to take tirabrutinib orally. Although oral administration is the standard route of administration for tirabrutinib, this case study showed that the nasogastric tube administration of tirabrutinib suspension is a therapeutic option for patients with impaired consciousness or dysphagia. - 奥田 武司Brain Nursing 37 3 381 - 382 (株)メディカ出版 2021年05月
- 奥田 武司Brain Nursing 37 3 383 - 384 (株)メディカ出版 2021年05月
- Takayuki Nakao; Takeshi Okuda; Hiromasa Yoshioka; Mitsugu FujitaAnticancer research 40 8 4801 - 4804 2020年08月 [査読有り]
BACKGROUND/AIM: Recent advances in systemic chemotherapy, including molecularly targeted therapy, have dramatically improved survival for patients with advanced non-small cell lung cancer. We retrospectively analyzed the clinical outcomes of surgical resection for brain metastases of non-small cell lung cancer cases performed at the Department of Neurosurgery of Kindai University Hospital, Osaka, Japan. PATIENTS AND METHODS: Craniotomy and tumor resection were performed for 56 patients with brain metastases of non-small cell lung cancer. Adenocarcinoma was the most common histological type, appearing in 40 cases, of which 18 were positive for driver gene mutations. RESULTS: Median survival for all 56 patients was 14.5 months, and single brain metastasis and adenocarcinoma were identified as favorable prognostic factors. Analysis limited to the 40 cases of adenocarcinoma identified single brain metastasis as a favorable prognostic factor. Although no significant difference was found for systemic chemotherapy, patients who received molecularly targeted therapy showed a better prognosis than those who received cytotoxic chemotherapy. Analyses of both the entire group and of adenocarcinoma patients alone found that whole-brain radiotherapy showed no significant association with survival. CONCLUSION: Single brain metastasis and adenocarcinoma were identified as favorable prognostic factors, but did not confirm any benefit from whole-brain radiotherapy. These results suggest that multimodal treatment strategies utilizing various methods of treatment, including systemic chemotherapy, may help prolong patient survival in the future. - Shoichi Deguchi; Yoko Nakasu; Tsukasa Sakaida; Jiro Akimoto; Kuniaki Tanahashi; Atsushi Natsume; Masamichi Takahashi; Takeshi Okuda; Hirofumi Asakura; Koichi Mitsuya; Nakamasa Hayashi; Yoshitaka NaritaInternational journal of clinical oncology 25 11 1995 - 2005 2020年07月 [査読有り]
BACKGROUND: Brain metastasis (BM) is an uncommon complication of sarcomas with a poor prognosis. Little information is available about the feasibility and prognostic factors of surgical resection of BM from sarcomas. METHODS: This study involved a retrospective analysis of 22 patients with BM from sarcomas who underwent resection at six institutes in Japan. Prognostic factors were analyzed to develop a graded prognostic assessment (GPA) using the log-rank test and Cox regression analysis. For validation of this GPA, we collected data on 100 surgical cases from 48 published reports. RESULTS: Postoperative Karnofsky Performance Status (KPS) improved in 50% of our patients. Median overall survival (OS) was 21 months. Multivariate analysis showed age and alveolar soft part sarcoma (ASPS) were significant preoperative prognostic factors (P < 0.05). RTOG-RPA classification had no significant prognostic value. We developed a GPA system for OS after resection of BM. A score of 0 was assigned to patients aged 18-29 years with non-ASPS, 2 to patients aged 18-29 years with ASPS or 30-76 years with non-ASPS, and 4 to patients aged 30-76 years with ASPS. Median OS for patients with GPA scores of 0, 2, and 4 were 6.5, 16.0, and 44.0 months, respectively (P = 0.002). The results were validated by the data of 100 cases compiled (P < 0.001). CONCLUSION: Median OS of patients with BM from sarcomas was comparable to that from carcinomas after resection. A new sarcoma-specific GPA may help patients and clinicians to select resection as an option for treatment of BM from sarcomas. - Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J Luis Espinoza; Maiko Komori-Inoue; Hiroaki Kakutani; Shuji Minamoto; Takahiro Kumode; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Takeshi Okuda; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraViruses 12 4 2020年04月 [査読有り]
Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein-Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity. - Takeshi Okuda; Mitsugu Fujita; Amami KatoAnticancer research 39 8 4491 - 4494 2019年08月 [査読有り]
BACKGROUND/AIM: High-mobility group box 1 (HMGB1) is a nuclear DNA-binding protein that exerts a range of proinflammatory actions when it is secreted extracellularly. We hypothesized that HMGB1 released from damaged cells in pituitary apoplexy would exacerbate the neurological symptoms due to acute inflammation. PATIENTS AND METHODS: All the patients included in this study suffered from non-functioning pituitary adenoma. Four patients with apoplexy and three patients without apoplexy were included in this study. They underwent endonasal transsphenoidal endoscopic surgery to resect the tumors. We conducted enzyme-linked immunosorbent assay (ELISA) to measure HMGB1 in the surgical specimens. RESULTS: Patients with apoplexy expressed HMGB1 at significantly higher levels than those in the non-apoplexy group (p=0.0478). CONCLUSION: HMGB1 may be involved in subacute inflammation of pituitary apoplexy. Further work is needed to elucidate the detailed biological significance of HMGB1 in this disease. - Shigeru Kawai; Takeshi Okuda; Ayano Fukui; Yasuhiro Sanada; Keisuke Yoshikawa; Miyuki Morikawa; Motoi Kuwahara; Osamu Maenishi; Yasuyoshi Morita; Shuichi Izumoto; Amami Kato; Itaru Matsumura; Susumu KusunokiInternal medicine (Tokyo, Japan) 58 14 2085 - 2089 2019年07月 [査読有り]
Intravascular lymphoma (IVL) is a malignant lymphoma that lacks the expression of cell surface adhesion molecules so that cells fluidly migrate within the blood vessels. The patient in the present study had restricted eye movement caused by IVL, mimicking a cavernous sinus tumor. Because the cavernous sinus lumen is divided into multiple compartments by trabeculae and venous channels, IVL tumor cells were trapped in these compartments, thus forming a mass, which subsequently extended into the contralateral cavernous sinus via the anterior and posterior intercavernous sinuses. This is a rare case of IVL forming a mass inside the cavernous sinus. - Takayuki Nakao; Takeshi Okuda; Mitsugu Fujita; Amami KatoSurgical neurology international 10 131 131 - 131 2019年 [査読有り]
Background: Leptomeningeal metastases (LM) pose the most difficult form of cancer metastasis to treat and portend a poor prognosis. Standard treatment has yet to be established, and intrathecal chemotherapy and whole- brain radiotherapy are administered on an empirical basis. Case Description: We report on a 46-year-old woman with LM from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. She was suffering from intractable headaches, severe nausea and vomiting, and cerebellar ataxia. Contrast-enhanced magnetic resonance imaging (MRI) revealed diffuse enhancement of the meninges, mainly in the posterior cranial fossa, and compression of the cerebellum by the profoundly thickened meninges. The first step in the treatment was decompression of the posterior cranial fossa to relieve intracranial hypertension. After surgery, her symptoms immediately improved. The second step was treatment with lapatinib at 1250 mg and capecitabine 1200 mg, which dramatically improved her symptoms and disappeared diffuse abnormal signal enhancement on MRI. Conclusion: We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine. - Takeshi Okuda; Nakamasa Hayashi; Masamichi Takahashi; Takeo Uzuka; Yoshiko Okita; Ryohei Otani; Toshiyuki Fujinaka; Mitsugu Fujita; Amami Kato; Yoshitaka Narita; Yoko NakasuInternational journal of clinical oncology 23 6 1095 - 1100 2018年12月 [査読有り]
INTRODUCTION: The introduction of systemic chemotherapy for advanced hepatocellular carcinoma in recent years has led to the prediction that cases of brain metastases from hepatocellular carcinoma will increase. However, because brain metastases from hepatocellular carcinoma are relatively rare, the characteristics of this pathology are poorly understood. METHODS: We carried out a multicenter retrospective study to verify the characteristics of brain metastases from hepatocellular carcinoma in Japan. RESULTS: A total of 38 patients were enrolled and patient characteristics were poor general condition in many patients due to the progression of primary cancers. Stereotactic radiosurgery/stereotactic radiotherapy alone was the most common treatment (39.5%), with best supportive care provided for 10.5%. Median survival was 6 months, the neurological death rate was 28%, and the rate of brain hemorrhage was high (39.5%). Overall survival was analyzed for correlations with age, etiology of chronic liver disease, albumin-bilirubin (ALBI) grade, RPA classification, control of the primary tumor, number of brain metastases, brain hemorrhage, surgical resection, and radiotherapy. In multivariate analysis, ALBI grade, number of brain metastases and brain hemorrhage showed statistically significant correlation. CONCLUSIONS: A multivariate analysis extracted three items-ALBI grade, number of brain metastases, and brain hemorrhage-as prognostic factors for survival of brain metastases from hepatocellular carcinoma. - Shuichi Izumoto; Masaharu Miyauchi; Takayuki Tasaki; Takeshi Okuda; Nobuhiro Nakagawa; Naoki Nakano; Amami Kato; Mitsugu FujitaAnticancer research 38 7 4361 - 4366 2018年07月 [査読有り]
BACKGROUND/AIM: Excessive extracellular glutamate activates AMPA-type glutamate receptors (AMPA receptors) and induces seizures. Antagonistic activation of AMPA receptors inhibits epilepsy and glioma growth in in vitro and in vivo studies. This study was conducted to evaluate the clinical impacts of perampanel (PER), a novel AMPA receptor antagonist, on seizures and tumor progression in glioma patients with uncontrollable epilepsy. PATIENTS AND METHODS: Twelve glioma patients with uncontrollable epilepsy were treated with PER. Seizure response, PER concentration, and tumor volume were assessed. RESULTS: Obvious seizure control was observed in 10 analyzed patients (100%) and 6 patients (60%) became seizure-free. Median plasma concentrations of PER were 296 ng/ml in those with 4 mg/day PER treatment and 518 ng/ml in those with 8 mg/day PER treatment. High-intensity lesions in fluid-attenuated inversion recovery of magnetic resonance imaging (MRI) were volumetrically assessed to analyze tumor size. Volume reduction was detected within 6 months in correlation with increased plasma levels of PER. CONCLUSION: PER treatment was effective in uncontrollable epilepsy with gliomas. MRI images showed the inhibition of tumor growth. - Takeo Uzuka; Hideaki Takahashi; Yoko Nakasu; Takeshi Okuda; Koichi Mitsuya; Nakamasa Hayashi; Takayuki Hirose; Hanako KuraiNEUROLOGIA MEDICO-CHIRURGICA 57 10 542 - 547 2017年10月 [査読有り]
Patients with malignant brain tumors are possibly at increased risk for surgical site infections (SSIs) considering the various medical situations associated with the disease. However, the actual rate of SSI after malignant brain tumor resection has not been well established, despite the potential impact of SSI on patient outcome. To investigate the incidence of SSI following malignant brain tumor surgery, we performed a retrospective study in 3 neurosurgical units. Subsequently, aiming at the reduction of incidence of SSI, we performed a prospective study using a care bundle technique in the same units. The SSI incidence in the retrospective (n = 161) and prospective studies (n = 68) were 4.3% and 4.4%, respectively, similar to the previously reports on general craniotomies. A care bundle does not appear to enhance prevention of SSI. However, future, large studies with a new care bundle should be planned based on a zero tolerance policy. - Successful treatment of large intracranial granulocytic sarcomasOkuda T; Kato A; Fujita MJournal of Clinical Neurology, Neurosurgery and Spine 1 1 112 2017年07月 [査読有り]
- Takeshi Okuda; Takayuki Tasaki; Susumu Nakata; Kimihiro Yamashita; Hiromasa Yoshioka; Shuichi Izumoto; Amami Kato; Mitsugu FujitaANTICANCER RESEARCH 37 7 3871 - 3876 2017年07月 [査読有り]
Background: Glioblastoma multiforme (GBM) is a malignant brain tumor with an extremely poor prognosis. GBM tissues frequently express mesenchymal-epithelial transition factor (MET), which induces cell division, growth and migration. In addition, angiogenesis is a significant feature of GBM, attributable to the overexpression of vascular endothelial growth factor (VEGF). Although the VEGF inhibitor bevacizumab was recently highlighted as the second-line drug for GBM treatment, GBMs often recur even with bevacizumab therapy. Based on these findings, we hypothesized that inhibition of both MET and VEGF would exhibit a synergistic effect on MET-overexpressing GBM. Materials and Methods: As we observed MET expression at high levels in some patients with GBM, we designed GL261 murine glioma-based experiments. GL261 cells were transfected with siRNAs specific for MET and VEGF in vitro, and the cell growth ratios were evaluated. Simultaneously, transfected GL261 cells were transplanted into the brain of C57BL/6 mice, and their survival was monitored. Results: GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas. These GBMs at first responded to bevacizumab, but often eventually recurred. When GL261 cells were co-transfected with both MET-specific siRNA and VEGF-specific siRNA, the in vitro tumor cell growth significantly decelerated compared to single siRNA transfection. Consistently, when mice were transplanted with co-transfected GL261 cells, their survival was significantly prolonged compared to those given cells transfected with single siRNA. Conclusion: The current data indicate that the inhibition of both MET and VEGF exhibits efficient therapeutic effects of GBM-bearing hosts. - Nakamasa Hayashi; Hideaki Takahashi; Yuzo Hasegawa; Fumi Higuchi; Masamichi Takahashi; Keishi Makino; Masatoshi Takagaki; Jiro Akimoto; Takeshi Okuda; Yoshiko Okita; Koichi Mitsuya; Yasuyuki Hirashima; Yoshitaka Narita; Yoko NakasuBMC CANCER 17 1 397 2017年06月 [査読有り]
Background: The prevalence of brain metastases (BM) from uterine cancer has recently increased because of the improvement of overall survival (OS) of patients with uterine cancer due to its early detection and improved local control as a result of new effective treatments. However, little information is available regarding their clinical characteristics and prognosis, because oncologists have encountered BM from uterine cancer on rare occasions. Methods: Records from 81 patients with uterine BM were collected from 10 institutes in Japan. These were used in a multi-institutional study to identify prognostic factors and develop a graded prognostic assessment (GPA) for patients with BM from uterine cancer. Results: Median OS after the development of BM was 7 months (95% confidence interval, 4 to 10 months). Multivariate analysis revealed that there were survival differences according to the existence of extracranial metastases and number of BM. In the present uterine-GPA, a score of 0 was assigned to those patients with >= 5 BM and extracranial metastasis, a score of 2 was assigned to those patients with one to four BM or without extracranial metastasis, and a score of 4 was assigned to those patients with one to four BM and without extracranial metastasis. The median OS for patients with a uterine-GPA scores of 0, 2, and 4 was 3, 7, and 22 months, respectively. A survival analysis confirmed the presence of statistically significant differences between these groups (p < 0.05). The results were validated by data obtained from the National Report of Brain Tumor Registry of Japan. Conclusion: Uterine GPA incorporates two simple clinical parameters of high prognostic significance and can be used to predict the expected survival times in patients with BM from uterine cancer. Its use may help in determining an appropriate treatment for individual patients with BM. - Kiyohiro Sakai; Masayuki Takeda; Hidetoshi Hayashi; Kaoru Tanaka; Takeshi Okuda; Amami Kato; Yasumasa Nishimura; Tetsuya Mitsudomi; Atsuko Koyama; Kazuhiko NakagawaTHORACIC CANCER 7 6 670 - 675 2016年11月 [査読有り]
IntroductionThe concept of oligometastasis has emerged as a basis on which to identify patients with stage IV non-small cell lung cancer (NSCLC) who might be most amenable to curative treatment. Limited data have been available regarding the survival of patients with node-negative oligometastatic NSCLC. Patients and methodsConsecutive patients with advanced NSCLC who attended Kindai University Hospital between January 2007 and January 2016 were recruited to this retrospective study. Patients with regional lymph node-negative disease and a limited number of metastatic lesions (5) per organ site and a limited number of affected organ sites (1 or 2) were eligible. ResultsEighteen patients were identified for analysis during the study period. The most frequent metastatic site was the central nervous system (CNS, 72%). Most patients (83%) received systemic chemotherapy, with only three (17%) undergoing surgery, for the primary lung tumor. The CNS failure sites for patients with CNS metastases were located outside of the surgery or radiosurgery field. The median overall survival for all patients was 15.9months, with that for EGFR mutation-positive patients tending to be longer than that for EGFR mutation-negative patients. ConclusionCure is difficult to achieve with current treatment strategies for NSCLC patients with synchronous oligometastases, although a few long-term survivors and a smaller number of patients alive at last follow-up were present among the study cohort. There is an urgent clinical need for prospective evaluation of surgical resection as a treatment for oligometastatic NSCLC, especially negative for driver mutations. - Takayuki Tasaki; Mitsugu Fujita; Takeshi Okuda; Azusa Yoneshige; Susumu Nakata; Kimihiro Yamashita; Hiromasa Yoshioka; Shuichi Izumoto; Amami KatoANTICANCER RESEARCH 36 7 3571 - 3577 2016年07月 [査読有り]
Background: Glioblastoma multiforme (GBM) is the most frequent and the most malignant tumor among adult brain tumors. Previous reports led us to hypothesize that the protooncogene mesenchymal-epithelial transition (MET) expressed in glioma stem cell-like cells (GSCs) would be a potent therapeutic target for GBM. Patients and Methods: To address this question, we analyzed 113 original samples of tumors from patients based on immunohistochemistry. During this process, we were able to establish GSC lines from patients with GBM that were MET-positive and MET-negative. Using these cells, we tested the therapeutic impact of a MET inhibitor, crizotinib, both in vitro and in vivo. Results: Patients with MET-positive GBM exhibited poor survival. GSC-based experiments revealed that treatment with crizotinib, both in vitro and in vivo, exhibited therapeutic efficacy particularly against MET-positive GSCs. Conclusion: Based on these findings, we conclude that MET expressed in GSCs might be a potent therapeutic target for GBM. - Endoscopic Biopsy using High-Dose Fluorescein Sodium for Malignant Brain TumorsOkuda T; Fujita M; Yoshioka H; Tasaki T; Izumoto S; Kato AInternational Journal of Neurology and Neurotherapy 3 3 052 2016年06月 [査読有り]
- Takayuki Tasaki; Takeshi Okuda; Kunio Okamoto; Hiromasa Yoshioka; Mitsugu Fujita; Shuichi Izumoto; Kazuhiko Nakagawa; Amami KatoJapanese Journal of Neurosurgery 24 3 192 - 197 2015年 [査読有り]
Glioblastoma multiforme (GBM) often infiltrates surrounding tissues, an action which is known as a clinical characteristic of this deadly disease. In contrast, extracranial metastases of GBM rarely occur. Consequently, the underlying mechanisms and prognosis of GBM metastasis remain unclear. In this regard, we here present a case of GBM with pleural metastases and discuss the relevant literature. The patient was a 62-year-old male who was originally diagnosed with GBM in the right temporal lobe and underwent craniotomy for tumor removal. Gross total resection was successfully performed. The patient received postoperative chemoradiotherapy with temozolomide, followed by maintenance chemotherapy with temozolomide alone. He showed a good postoperative course until a small recurrence occurred in the resection cavity at 17 months after the surgery. At 21 months, the patient developed thoracodorsal pain due to a large volume of pleural effusion with pleural masses. An intrathoracic biopsy revealed that the pleural lesions were metastases of the GBM. Simultaneously, intracranial imaging studies indicated tumor spread into the right cavernous sinus. These findings suggest that the GBM may have infiltrated into the cavernous sinus via the dura surrounding the cavernous sinus adjacent to the resection cavity and metastasized hematogenously to the pleural cavity - Hidetoshi Hayashi; Isamu Okamoto; Junko Tanizaki; Kaoru Tanaka; Takeshi Okuda; Amami Kato; Yasumasa Nishimura; Kazuhiko NakagawaJOURNAL OF CLINICAL ONCOLOGY 32 36 E122 - E124 2014年12月 [査読有り]
- Mitsugu Fujita; Susumu Nakata; Takeshi Okuda; Amami Kato; Osamu YoshieCANCER RESEARCH 74 19 2014年10月 [査読有り]
- Takeshi Okuda; Juli Yamashita; Mitsugu Fujita; Hiromasa Yoshioka; Takayuki Tasaki; Amami KatoACTA NEUROCHIRURGICA 156 7 1403 - 1407 2014年07月 [査読有り]
We verified the effectiveness of training in endoscopic endonasal transsphenoidal surgery (eETSS) techniques using chicken eggs and a skull model. We verified the area of eggshell removed by drilling when five residents and four experts used the chicken eggs and a skull model. When residents performed drilling on 10 eggs, a mean (+/- standard deviation [SD]) area of 31.2 +/- 17.5 mm2 was removed from the first egg, and 104.8 +/- 3.3 mm2 from the tenth and final egg, representing an increase in area and a decrease in SD. The experts performed the same drilling operation on a single egg, and removed a mean area of 257 +/- 31.7 mm2. These results demonstrated that skills improved as a result of this training, and suggested that this method was also capable of overcoming the initial individual differences in the amount of force applied and ability. An obvious difference between residents and experts was seen in the area removed (p = 0.00011); however, this was attributed to differences in endoscopic manipulation, rather than drilling skill. Our findings suggest that this training method could be adequate for acquiring eETSS techniques. Although experts showed superior endoscopic manipulation, residents may also be able to acquire adequate endoscopic skills through further training, and our training method appears to offer an effective means of improving eETSS techniques. - Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosisOkuda T; Hayashi H; Fujita M, T; Yoshioka H; Tasaki T; Nakagawa K; Kato AInternational Cancer Conference Journal 3 211 - 214 2014年03月 [査読有り]
- Takeshi Okuda; Mitsugu Fujita; Hiromasa Yoshioka; Takayuki Tasaki; Amami KatoSurgical Neurology International 5 2014年 [査読有り]
Background: An outstanding issue regarding the surgical treatment of cyst-type metastatic brain tumors is the incomplete resection of cyst walls. Herein we propose a novel surgical technique that can overcome this issue. During a surgical procedure for cystic tumors, autologous fibrin glue is to be injected into the tumor cysts, which solidifies the cyst lumens and cyst walls en bloc with reducing the tumor size. As a result, tumor masses and cyst walls can be removed completely in an en bloc fashion in all cases. Copyright: Methods: The illustrative case presented in this report is a patient with metastatic brain tumors in the frontal lobe. When we reached the tumor wall surgically, we first suctioned out the cyst content and subsequently injected autologous fibrin glue into the cyst lumen. The autologous fibrin glue solidified the tumor en bloc, and we resected the tumor mass and the cyst walls in an en bloc fashion. Results: We have applied this technique to four cases with cyst-type metastatic brain tumors. This approach made it possible to perform ideal en bloc resection in all cases. There were no adverse events due to the autologous fibrin glue. Conclusion: We developed a novel surgical technique to solidify cyst-type metastatic brain tumors using autologous fibrin glue, which allows en bloc resection of tumor masses and cyst walls quite safely using inexpensive materials. Given these advantages, it appears a promising surgical strategy for cyst-type metastatic brain tumors. - Yoshioka H; Okuda T; Fujita M; Inoue T; Tasaki T; Izumoto S; Kato AActa M ed Kinki Univ 39 2 105 - 113 Kinki University Medical Association 2014年 [査読有り]
[Abstract] Current evidence indicates that glioma stem cell-like cells (GSC_S) in humans play critical roles in the pathogenesis of carcinogenesis ofglioblastoma (GBM ). The GSC_S are known to overexpress members of the adenosine triphosphate-binding cassette (ABC) family transporters to exhibit multidrug resistance. Eradication of the GSC compartment is therefore essential to achieve a stable and long-lasting remission of GBM. To elucidate the characteristics of GSC_S in detail, we generated murine GSC lines from Sleeping Beauty transposon-mediated spontaneous GBM . Using these several cell lines, we evaluated the significance of ABC transporters in the GSC kinetics by cell morphology assays, flow cytometry, and quantitativeRT-PCR for mRNA expressions. As a consequence, we show that siRNA-mediated ABCG2 inhibition enhances the sensitivity of GSC_S to temozolomide (TMZ) and in turn reduces their spheroid-forming capability. Furthermore, we show that GSC_S treated with Abcg2-specific siRNA become sensitive to TMZ and reduce their spheroid-forming capability. In conclusion, our data suggest that targeting of drug transporters in GSC_S is a promising strategy to enhance their chemo-sensitivity for achieving a longlasting remission of GBM . - Okuda T; Fujita M; Yoshioka H; Tasaki T; Kato ASurgical neurology international 5 100 - 100 2014年 [査読有り]
BACKGROUND: An outstanding issue regarding the surgical treatment of cyst-type metastatic brain tumors is the incomplete resection of cyst walls. Herein we propose a novel surgical technique that can overcome this issue. During a surgical procedure for cystic tumors, autologous fibrin glue is to be injected into the tumor cysts, which solidifies the cyst lumens and cyst walls en bloc with reducing the tumor size. As a result, tumor masses and cyst walls can be removed completely in an en bloc fashion in all cases. METHODS: The illustrative case presented in this report is a patient with metastatic brain tumors in the frontal lobe. When we reached the tumor wall surgically, we first suctioned out the cyst content and subsequently injected autologous fibrin glue into the cyst lumen. The autologous fibrin glue solidified the tumor en bloc, and we resected the tumor mass and the cyst walls in an en bloc fashion. RESULTS: We have applied this technique to four cases with cyst-type metastatic brain tumors. This approach made it possible to perform ideal en bloc resection in all cases. There were no adverse events due to the autologous fibrin glue. CONCLUSION: We developed a novel surgical technique to solidify cyst-type metastatic brain tumors using autologous fibrin glue, which allows en bloc resection of tumor masses and cyst walls quite safely using inexpensive materials. Given these advantages, it appears a promising surgical strategy for cyst-type metastatic brain tumors. - Rieko Okada; Takeshi Okuda; Naoki Nakano; Kazuhiko Nishimatsu; Hiroyuki Fukushima; Minori Onoda; Toshiho Otsuki; Kazunari Ishii; Takamichi Murakami; Amami KatoJOURNAL OF NEUROLINGUISTICS 26 4 470 - 478 2013年07月 [査読有り]
The aim of this study was to identify the location associated with primitive sentence processing. Processing related to generation and comprehension of sentences ("sentence processing") is postulated to be largely divided into syntactic processing (processing related to the formation of sentences and to verb reflection and particles) and verb information (argument structure and thematic role). Numerous lesion studies and functional brain imaging studies on unimpaired individuals have suggested that the left inferior frontal gyrus (IFG) is involved in syntactic processing. In addition, some studies have reported that the area from the left parietal lobe to the posterior superior temporal gyrus is involved in processing information such as argument structure and thematic role. However, studies on sentence processing using functional brain imaging have used complex sentences as tasks, raising the possibility that the results show the demands on not only language processing, but also on working memory. To clarify the brain areas involved in basic sentence processing in human language, there is a need to examine tasks involved in sentence processing that assume more primitive processing with minimal demands on working memory. The present study used sentence-completion tasks in the Japanese language that include basic sentence processing. The results showed activation in the left IFG and left parietal lobe, suggesting that these areas are involved in sentence processing. We then investigated the proportion of patients showing impaired sentence processing from among patients with aphasia and a lesion in the left IFG or from the parietal lobe to the posterior superior temporal gyrus. Four of 5 patients (80%) with lesions mostly in the left IFG showed impaired sentence processing, suggesting that this site plays a critical role in sentence processing. Of the 4 patients with lesions mostly in the area from the left parietal lobe to the posterior superior temporal gyrus, 1 patient (25%) showed impaired sentence processing. Unlike the other 3 subjects, this subject exhibited impaired recalling of verbs. This area is mainly involved in lexical-semantics and the present results suggest that verb information within that field became impaired, in turn causing impaired sentence processing. (C) 2013 Elsevier Ltd. All rights reserved. - Takeshi Okuda; Hiromasa Yoshioka; Amami KatoJOURNAL OF CLINICAL NEUROSCIENCE 19 12 1719 - 1722 2012年12月 [査読有り]
We have developed a technique of fluorescence-guided surgery using high-dose fluorescein sodium (20 mg/kg) with excitation and barrier filters for glioblastoma multiforme surgery. This technique was used in 10 patients, with surgery proceeding as expected in all patients. There were no complications or permanent side effects. This method uses filters to help distinguish between the usually invisible tumor and the brain surface, as well as allowing a detailed assessment of the positional relationships with tumor vessels and the surrounding normal vessels. As sufficient yellow staining was present even without filters, delicate microsurgery was also possible under a normal white-light microscope. Both environments could be used as necessary during surgery according to the requirements of resection, thereby improving the reliability and safety of surgery. (C) 2012 Elsevier Ltd. All rights reserved. - Takeshi Okuda; Kazuo Kataoka; Amami KatoACTA NEUROCHIRURGICA 152 10 1801 - 1804 2010年10月 [査読有り]
Recently, endoscopic pituitary surgery is increasingly being used in pituitary surgery. Compared to conventional microscopic pituitary surgery, outcomes have been non-inferior, so endoscopic pituitary surgery has become an established surgical technique. However, this is a highly specialized surgery and sophisticated surgical techniques are required. We report our development of a training model for endoscopic endonasal transsphenoidal surgery. Our training model is constructed using a skull model and eggs. The sella turcica of the skull model is hollowed out and an egg is placed. The bottom of the egg simulates the sella turcica floor and the egg contents simulate a tumor. Training is conducted using this model in an actual operating room with actual surgical instruments. This model is highly realistic and is within acceptable limits as a surgical simulation. Since practice can be repeated, this model is effective for familiarization with endoscopic imaging and to increase technical skills such as drilling and curetting. In addition, variations in eggs, ranging from raw eggs to boiled eggs, can be used to simulate various tumors for training. This training model using a skull model and eggs is useful to improve surgical techniques in endoscopic endonasal transsphenoidal surgery. - Yusuke Yamazaki; Motonao Yagi; Naoki Nakano; Naohiro Tsuyuguchi; Takeshi Okuda; Haruki Yugami; Rieko Okada; Sadao Shiosaka; Amami Kato; Yoshinobu HaraNEUROSCIENCE RESEARCH 68 E440 - E441 2010年 [査読有り]
- Takeshi Okuda; Kazuo Kataoka; Tomonari Yabuuchi; Haruki Yugami; Amami KatoJOURNAL OF CLINICAL NEUROSCIENCE 17 1 118 - 121 2010年01月 [査読有り]
We aimed to demonstrate the effectiveness of fluorescence-guided surgery of metastatic brain tumors using fluorescein sodium. The study comprised 38 patients with metastatic brain tumors who underwent tumor resection after intravenous injection of fluorescein sodium. The local recurrence rate was investigated in 36 of the 38 patients, and compared for patients who had undergone surgery only and surgery plus whole-brain radiotherapy (WBRT). In 31 of 36 patients, the tumors had been completely resected using fluorescence-guided surgery. Postoperative WBRT was not performed in 20 of the 31 patients who underwent gross total resection. Although the recurrence rate for these 20 patients was 20%, compared to 9.1% for the 11 patients who also underwent postoperative WBRT, the difference was not statistically significant. Use of fluorescein sodium in metastatic brain tumor surgery may reduce the rate of local recurrence, and thus help improve the quality of life for these patients. (C) 2009 Elsevier Ltd. All rights reserved. - Takeshi Okuda; Yoshifumi Teramoto; Haruki Yugami; Kazuo Kataoka; Amami KatoSURGICAL NEUROLOGY 72 6 703 - 706 2009年12月 [査読有り]
Background: Many metastatic brain tumors have a distinct border with normal brain tissue, which facilitates tumor removal. However, residual tumor tissue may be present after surgery when metastatic brain tumors are of cystic type. We have developed a method using hydrofiber dressing to transform cystic-type into solid-type tumors. Methods: Hydrofiber dressing is a sodium carboxymethylcellulose hydrocolloid polymer with high fluid-absorptive capacity. This material was originally used as a dressing for exudative wounds. Hydrofiber dressing was used for 8 patients with cystic-type metastatic brain tumor. Tumor removal was performed after hydrofiber dressing was inserted into the cyst cavity to transform the tumor into a solid-type tumor. Results: Transformation of cystic-type metastatic brain tumors into smaller solid-type tumors using hydrofiber dressing facilitated en bloc resection of tumor. The dressing also absorbed residual cyst fluid and was thus also effective in preventing intraoperative dissemination of tumor cells. This approach enabled ideal en bloc resection in all patients. There were no adverse events. Conclusions: These findings suggest hydrofiber dressing may be useful in surgery for cystic-type metastatic brain tumors. (C) 2009 Elsevier Inc. All rights reserved. - Takeshi Okuda; Kazuo Kataoka; Amami KatoJapanese Journal of Cancer and Chemotherapy 36 4 599 - 603 2009年 [査読有り]
Leptomeningeal carcinomatosis is a serious complication leading to a fatal outcome in patients with gastric cancer. We tried to treat leptomeningeal carcinomatosis from gastric cancer with intrathecal chemotherapy using methotrexate (MTX) and cytosine arabinoside (Ara-C). We described and discussed the therapeutic strategy. Six patients with leptomeningeal carcinomatosis from gastric cancer were admitted in our institution from March 2004 to July 2007. Three of 6 patients were accepted for intrathecal chemotherapy. They received intraventricular injections of MTX (5 mg) and Ara-C (20 mg) through the Ommaya reservoir. The other 3 patients who rejected the therapy were conservatively treated with betamethasone, carbamazepine and glyceol. Two of the intrathecal chemotherapy group received whole-brain radiotherapy after the initial intrathecal chemotherapy. The mean survival time was 122. 3 days (median survival time 35. 0 days). The survival of the intrathecal chemotherapy group was from 39 to 367 days, whereas the survival of the conservative treatment group was from 10 to 31 days. The intrathecal chemotherapy improved not only survival but also clinical symptoms dramatically. Intrathecal chemotherapy is thus recommended for leptomeningeal carcinomatosis from gastric cancer. - Okuda T; Kataoka K; Kato ANo shinkei geka. Neurological surgery 36 11 1001 - 1004 2008年11月 [査読有り]
- Takeshi Okuda; Fumiharu Akai; Kazuo Kataoka; Mamoru TanedaBRAIN TUMOR PATHOLOGY 25 1 33 - 38 2008年04月 [査読有り]
Lymphomatoid granulomatosis (LYG) is a systemic granulomatous disease characterized by B-cell proliferation of uncertain malignant potential. It most frequently affects the lungs but also occasionally affects the central nervous system. Its pathophysiology is unclear in numerous respects, thus making it difficult to diagnose and treat. We recently encountered a case of LYG that was followed clinically and histologically for 14 months. A 55-year-old man was hospitalized with multiple brain tumors for which the final diagnosis was not made until the second surgery, 14 months after the first intervention. Following the diagnosis, he was treated with steroid pulse therapy. At present, 3.5 years after the onset of LYG, the patient is in good condition with no signs of tumor recurrence. Although LYG is usually graded on the basis of histological findings, this patient showed no histological changes or any increase in disease grade during the 14-month follow-up period. - T. Okuda; K. Kataoka; M. TanedaMINIMALLY INVASIVE NEUROSURGERY 50 6 382 - 384 2007年12月 [査読有り]
As for the surgical treatment of glioma, the recent employment of fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) or high-dose fluorescein sodium has increased the rate of radical tumor resection. On the other hand, there is no specific technique for metastatic brain tumor surgery. We have used a fluorescence-guided tumor resection procedure with the aid of high-dose fluorescein sodium in surgery for metastatic brain tumor. Fluorescein sodium has been used in 13 cases, and achieved effective stainability in all cases. Fluorescein sodium is inexpensive, highly safe, and comparatively easy to use, and does not require any special equipment. We believe that the use of fluorescein sodium is beneficial for resection of the metastatic brain tumor. - Takeshi Okuda; Masahiko Kitano; Mamoru TanedaNeurological Surgery 34 11 1119 - 1123 2006年11月 [査読有り]
A transcranial approach is frequently employed for the closure of cerebrospinal fluid (CSF) rhinorrhea, occurring after skullbase surgery or associated with anterior skull base fracture. However, the site of CSF rhinorrhea is usually most distant from the site of craniotomy and, because securing of an adequate operative field is difficult, elimination of this type of CSF rhinorrhea tends to be insufficient. We have attempted to reconstruct the anatomical structures with an extended transsphenoidal approach for a case with CSF rhinorrhea from the planum sphenoidale, and have succeeded in achieving a more physiological and reliable elimination of CSF rhinorrhea. This technique is presented, with a representative example. - T. Okuda; Kazuo Kataoka; M. Kitano; A. Watanabe; M. TanedaMinimally Invasive Neurosurgery 48 4 247 - 249 2005年08月 [査読有り]
Chronic cerebrospinal fluid (CSF) leaks associated with skull base fractures are rare but intractable and patients may be subjected to numerous operations. We present a 30-year-old man with a 13-year history of chronic CSF rhinorrhea following a cranial trauma. Computed tomography (CT) showed a bone defect in the planum sphenoidale. CT cisternography revealed a leak from the defect and CSF malabsorption. The absence of symptoms of CSF malabsorption may be attributable to external leakage of excess CSF. After closing the leak via the extended transsphenoidal approach we placed a ventriculoperitoneal shunt for occult hydrocephalus. We discuss the clinical symptoms of chronic CSF leakage and present therapeutic strategies dictated by the mechanisms underlying the leak. © Georg Thieme Verlag KG Stuttgart. - N Nakano; T Uchiyama; T Okuda; M Kitano; M TanedaJOURNAL OF NEUROSURGERY 102 6 1137 - 1141 2005年06月 [査読有り]
The authors report a case of hemichorea-hemiballism (HC-HB) that was successfully treated using deep brain stimulation (DBS). A 65-year-old right-handed man exhibited a sudden onset of right HC-HB without a diabetic coma. At admission T-1-weighted magnetic resonance (MR) images revealed a high-intensity signal in the left striatum, contralateral to the patient's involuntary movements. The HC-HB continued for 5 months after onset of the condition despite medical treatment and a decreased intensity of the signal on T-1-weighted MR images. The patient underwent placement of a quadripolar DBS electrode in the left thalamus, including the left ventral oralis (VO) anterior and posterior nuclei (the VO complex). Postoperatively, the right-sided HC-HB disappeared rapidly during electrical stimulation and there were no neurological deficits. The authors demonstrate that DBS can be an effective treatment for medically refractory HC-HB. This is the first case of HC-HB that has been successfully treated with DBS. - Takeshi Okuda; Fumiharu Akai; Naoki Nakano; Takuya Uchiyama; Mamoru TanedaBrain and Nerve 55 1 65 - 69 2003年01月 [査読有り]
A 40-year-old man with intractable meningitis was transferred to our hospital 6 weeks after onset. On admission, he showed consciousness disturbance, meningeal signs and right oculomotor nerve palsy. MRI demonstrated prominent cisternal enhancement and hydrocephalus. We suspected tuberculous meningitis as the diagnosis, and treated with antituberculotics, though he died of midbrain infarction day 11 of the treatment. Before and during the admission, bacterial cultures, PCR, smear examination of cerebrospinal fluid (CSF) were repeated. But no evidence of tuberculosis was obtained. Cultures of the brainstem fragments detected mycobacterium, which was finally confirmed by a PCR method after his death. PCR provides a rapid and reliable diagnosis of tuberculous meningitis, although there is a potential for false-negative. Thus the clinical, radiological and CSF findings should be stressed. Corticosteroids treatment should be considered in cases with ischemic lesions.
MISC
- 吉岡宏真; 奥田武司; 中尾剛幸; 藤田貢; 高橋淳 日本正常圧水頭症学会プログラム・抄録集 24th 2023年
- 奥田武司; 吉岡宏真; 中尾剛幸; 藤田貢; 高橋淳 日本脳腫瘍の外科学会プログラム・抄録集 28th 2023年
- 奥田武司; 吉岡宏真; 中尾剛幸; 藤田貢; 高橋淳 日本脳腫瘍の外科学会プログラム・抄録集 27th 2022年
- 奥田武司; 古川健太郎; 布川知史; 吉岡宏真; 高橋淳 日本頭蓋底外科学会プログラム・抄録集 34th 2022年
- 吉岡宏真; 奥田武司; 中岡良介; 藤田貢; 高橋淳 Geriatric Neurosurgery (Web) 35 2022年
- 奥田武司; 藤田貢; 加藤天美 Brain Tumor Pathology (Web) 36 (Supplement) 2019年
- 奥田武司; 山下樹里; 田崎貴之; 加藤天美 日本神経内視鏡学会プログラム・抄録集 25th 101 2018年10月
- 神経膠腫に合併したてんかん患者におけるペランパネルの発作抑制効果と腫瘍抑制効果(Response to seizure and tumor-progression by perampanel in uncontrollable epilepsy with gliomas)藤田 貢; 田崎 貴之; 宮内 正晴; 奥田 武司; 中川 修宏; 中野 直樹; 加藤 天美; 泉本 修一 日本癌学会総会記事 77回 913 -913 2018年09月
- 奥田武司; 山下樹里; 田崎貴之; 露口尚弘; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 23rd 138 2018年09月
- 奥田武司; 藤田貢; 藤田貢; 露口尚弘; 加藤天美 日本間脳下垂体腫瘍学会プログラム・抄録集 28th 129 2018年01月
- 奥田武司; 藤田貢; 藤田貢; 加藤天美 バイオ治療法研究会学術集会プログラム・抄録集 22nd 2018年
- 田崎貴之; 泉本修一; 宮内正晴; 奥田武司; 中川修宏; 中野直樹; 加藤天美; 藤田貢 バイオ治療法研究会学術集会プログラム・抄録集 21st 31 2017年11月
- 奥田武司; 山下樹里; 田崎貴之; 加藤天美 日本神経内視鏡学会プログラム・抄録集 24th 133 2017年10月
- グリオーマ幹細胞における薬剤排出分子ABCG2の役割藤田 貢; 田崎 貴之; 奥田 武司; 米重 あずさ; 中田 晋 Cytometry Research 27 (Suppl.) 66 -66 2017年06月
- 海綿静脈洞に発生した血管内リンパ腫の1例奥田 武司; 河合 滋; 眞田 寧皓; 前西 修; 泉本 修一; 加藤 天美 Brain Tumor Pathology 34 (Suppl.) 137 -137 2017年05月
- 奥田武司; 山下樹里; 加藤天美 日本間脳下垂体腫よう学会プログラム・抄録集 27th 91 2017年02月
- Masayuki Takeda; Kiyohiro Sakai; Hidetoshi Hayashi; Kaoru Tanaka; Takeshi Okuda; Amami Kato; Yasumasa Nishimura; Tetsuya Mitsudomi; Atsuko Koyama; Kazuhiko Nakagawa JOURNAL OF THORACIC ONCOLOGY 12 (1) S892 -S893 2017年01月
- 藤田貢; 田崎貴之; 奥田武司; 吉岡宏真; 泉本修一; 加藤天美 日本免疫治療学研究会学術集会プログラム・抄録集 14th 34 2017年
- 泉本修一; 宮内正晴; 田崎貴之; 奥田武司; 中川修宏; 中野直樹; 加藤天美 日本脳腫瘍学会プログラム・抄録集 35th 164 2017年
- 奥田武司; 山下樹里; 田崎貴之; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 22nd 184 2017年
- 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司 肺癌 56 (7) 1072 -1072 2016年12月
- 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司 肺癌 56 (7) 1072 -1072 2016年12月
- 奥田武司; 藤田貢; 藤田貢; 田崎貴之; 中田晋; 山下公大; 吉岡宏真; 泉本修一; 加藤天美 バイオ治療法研究会学術集会プログラム・抄録集 20th 32 2016年12月
- 奥田武司; 山下樹里; 加藤天美 日本神経内視鏡学会プログラム・抄録集 23rd 192 2016年10月
- 子宮 婦人科がん治療の新展開 子宮がん脳転移の患者における生存期間予測と治療指針 新しいGPAの開発と検証林 央周; 高橋 英明; 長谷川 祐三; 樋口 芙未; 高橋 雅道; 牧野 敬史; 高垣 匡寿; 秋元 治朗; 奥田 武司; 沖田 典子; 三矢 幸一; 平嶋 泰之; 成田 善孝; 中洲 庸子 日本癌治療学会学術集会抄録集 54回 WS61 -1 2016年10月
- METの膠芽腫幹細胞関連抗原としての可能性藤田 貢; 田崎 貴之; 奥田 武司; 米重 あずさ; 中田 晋; 山下 公大; 加藤 天美 日本がん免疫学会総会プログラム・抄録集 20回 126 -126 2016年06月
- 膠芽腫におけるMET遺伝子発現の臨床的意義奥田 武司; 藤田 貢; 田崎 貴之; 中田 晋; 吉岡 宏真; 泉本 修一; 加藤 天美 Brain Tumor Pathology 33 (Suppl.) 109 -109 2016年05月
- 胸髄転移を認めた、著しい繊維化を伴う透明中隔部gliosarcomaの一例田崎 貴之; 泉本 修一; 長束 一紘; 奥田 武司; 中西 欣弥; 加藤 天美; 筑後 孝章 Brain Tumor Pathology 33 (Suppl.) 137 -137 2016年05月
- 泉本修一; 友金祐介; 奥田武司; 眞田寧晧; 加藤天美 Neuro-Oncologyの進歩(Web) 23 (1) 34 -34 2016年04月
- 頭蓋内血管周皮腫(SFTの亜型として)の診断、治療と長期予後泉本 修一; 友金 祐介; 奥田 武司; 眞田 寧晧; 加藤 天美 Neuro-Oncologyの進歩 23 (1) 27 -34 2016年04月
- 加藤了資; 酒井瞳; 原谷浩司; 高濱隆幸; 谷崎潤子; 吉田健史; 岩朝勤; 田中薫; 林秀敏; 武田真幸; 中川和彦; 古川健太郎; 奥田武司 肺癌(Web) 56 (7) 1072(J‐STAGE) 2016年
- 奥田武司; 泉本修一; 吉岡宏真; 田崎貴之; 加藤天美 日本老年脳神経外科学会プログラム・抄録集 29th 73 2016年
- 泉本修一; 奥田武司; 田崎貴之; 友金祐介; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 21st 175 2016年
- 泉本修一; 奥田武司; 田崎貴之; 友金祐介; 加藤天美 日本脳腫瘍学会プログラム・抄録集 34th 81 2016年
- 田崎貴之; 田崎貴之; 藤田貢; 藤田貢; 奥田武司; 吉岡宏真; 加藤天美 バイオ治療法研究会学術集会プログラム・抄録集 19th 33 2015年12月
- 奥田 武司 脳神経外科速報 25 (12) 1307 -1315 2015年12月
- FUJITA Mitsugu; YOSHIOKA Hiromasa; OKUDA Takeshi; NAKATA Susumu; MIYATAKE Shin‐Ichi; KATO Amami; YOSHIE Osamu 日本免疫学会総会・学術集会記録 44 (Proceedings) 51 2015年10月
- 腫瘍内M2マクロファージにおけるB7-H3およびB7-H5発現量は肺癌原発転移性脳腫瘍の発症と相関する藤田 貢; 奥田 武司; 中田 晋; 菰原 義弘; 加藤 天美; 義江 修 日本癌学会総会記事 74回 E -1141 2015年10月
- 子宮 子宮体がん治療の新たな工夫 子宮癌脳転移の予後予測因子に関する多施設共同研究林 央周; 高橋 英明; 長谷川 祐三; 樋口 芙未; 高橋 雅道; 牧野 敬史; 高垣 匡寿; 秋元 治朗; 奥田 武司; 沖田 典子; 三矢 幸一; 平嶋 泰之; 成田 善孝; 中洲 庸子 日本癌治療学会誌 50 (3) 1130 -1130 2015年09月
- 脳神経 脳腫瘍治療の最新情報 多施設共同による肝細胞癌原発脳転移の実態調査奥田 武司; 林 央周; 高橋 雅道; 沖田 典子; 藤中 俊之; 加藤 天美; 成田 善孝; 中洲 庸子 日本癌治療学会誌 50 (3) 2213 -2213 2015年09月
- 脳神経 脳腫瘍治療の最新情報 多施設共同による肝細胞癌原発脳転移の実態調査奥田 武司; 林 央周; 高橋 雅道; 沖田 典子; 藤中 俊之; 加藤 天美; 成田 善孝; 中洲 庸子 日本癌治療学会誌 50 (3) 2213 -2213 2015年09月
- 田崎 貴之; 泉本 修一; 奥田 武司; 佐藤 隆夫; 加藤 天美 Brain Tumor Pathology 32 (Suppl.) 098 -098 2015年05月
- 田崎 貴之; 奥田 武司; 岡本 邦男; 吉岡 宏真; 藤田 貢; 泉本 修一; 中川 和彦; 加藤 天美 脳神経外科ジャーナル 24 (3) 192 -198 2015年03月
- 奥田武司; 藤田貢; 田崎貴之; 泉本修一; 加藤天美 日本間脳下垂体腫よう学会プログラム・抄録集 25th 87 2015年02月
- 奥田武司; 吉岡宏真; 田崎貴之; 泉本修一; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 20th 97 2015年
- 泉本修一; 奥田武司; 城間淳; 田崎貴之; 友金祐介; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 20th 89 2015年
- 泉本修一; 尾路祐介; 清原英司; 森井英一; 橋本直哉; 友金祐介; 奥田武司; 杉山治夫; 加藤天美 日本脳腫瘍学会プログラム・抄録集 33rd 182 2015年
- FUJITA Mitugu; OKUDA Takeshi; NAKATA Susumu; KOMOHARA Yoshihiro; KATO Amami; YOSHIE Osamu 日本癌学会学術総会抄録集(Web) 74th E-1141 (WEB ONLY) 2015年
- 【苦手から一歩ぬけ出す!ICUでの脳神経看護-脳の解剖生理・疾患を知って的確なケアをするために-】 疾患 髄膜炎・脳膿瘍の診断、治療 中枢神経系の感染症は早期診断・迅速な抗菌薬開始が大事奥田 武司; 藤田 貢; 加藤 天美 急性・重症患者ケア 3 (2) 301 -308 2014年05月
- 奥田武司; 田崎貴之; 藤田貢; 泉本修一; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 19th 125 2014年
- 泉本修一; 友金祐介; 奥田武司; 田崎貴之; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 19th 144 2014年
- 泉本修一; 友金祐介; 有田憲生; 奥田武司; 田崎貴之; 加藤天美 日本脳腫瘍学会プログラム・抄録集 32nd 106 2014年
- 奥田武司; 藤田貢; 田崎貴之; 吉岡宏真; 泉本修一; 加藤天美 日本脳腫瘍学会プログラム・抄録集 32nd 98 2014年
- FUJITA Mitsugu; OKUDA Takeshi; NAKATA Susumu; KOMOHARA Yoshihiro; IZUMIMOTO Shuichi; KATO Amami; YOSHIE Osamu 日本脳腫瘍学会プログラム・抄録集 32nd 113 2014年
- 奥田武司; 吉岡宏真; 田崎貴之; 藤田貢; 加藤天美 日本癌治療学会学術集会(CD-ROM) 51st (3) ROMBUNNO.P72-4 -2597 2013年09月
- 奥田 武司; 山下 樹里; 吉岡 宏真; 田崎 貴之; 加藤 天美 脳神経外科速報 23 (3) 331 -336 2013年03月
- 吉岡宏真; 藤田貢; 奥田武司; 田崎貴之; 加藤天美 日本脳腫瘍学会プログラム・抄録集 31st 156 2013年
- 田崎貴之; 奥田武司; 吉岡宏真; 藤田貢; 加藤天美 日本脳腫瘍学会プログラム・抄録集 31st 74 2013年
- 奥田武司; 吉岡宏真; 田崎貴之; 藤田貢; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 18th 89 2013年
- 奥田武司; 金田裕靖; 吉岡宏真; 田崎貴之; 藤田貢; 中川和彦; 加藤天美 日本脳腫瘍学会プログラム・抄録集 31st 162 2013年
- 久保田尚; 真田寧皓; 薮内伴成; 吉岡宏真; 岩倉倫裕; 辻潔; 奥田武司; 布川知史; 中野直樹; 内山卓也; 加藤天美 脳循環代謝 24 (1) 181 -181 2012年11月
- 奥田武司; 吉岡宏真; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 17th 76 2012年
- 奥田武司; 山下樹里; 吉岡宏真; 田崎貴之; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 17th 76 2012年
- 山崎裕介; 八木一乃大; 中野直樹; 露口尚弘; 奥田武司; 湯上春樹; 岡田理恵子; 塩坂貞夫; 加藤天美; 原嘉信 解剖学雑誌 86 (2) 60 -60 2011年06月
- 奥田武司; 加藤天美 日本間脳下垂体腫よう学会プログラム・抄録集 21st 74 2011年02月
- 奥田武司; 加藤天美 日本頭痛学会誌 37 (2) 262 -262 2010年11月
- 原嘉信; 山崎裕介; 八木一乃大; 中野直樹; 露口尚弘; 奥田武司; 岡田理恵子; 塩坂貞夫; 加藤天美 てんかん研究 28 (2) 232 -232 2010年09月
- 脳腫瘍治療の新潮流(転移性脳腫瘍を含む) 転移性脳腫瘍連続100例の手術成績奥田 武司; 加藤 天美 日本癌治療学会誌 45 (2) 383 -383 2010年09月
- ヒト大脳・小脳皮質スライスの細胞構築と多電極システムによる神経活動の解析(Analysis of cytoarchitecture and electrical activity of the human cerebral and cerebellar cortical slices with multi-electrode array system)山崎 裕介; 八木 一乃大; 中野 直樹; 露口 尚弘; 奥田 武司; 湯上 春樹; 岡田 理恵子; 塩坂 貞夫; 加藤 天美; 原 嘉信 神経化学 49 (2-3) 769 -769 2010年08月
- 田村 英紀; 山崎 裕介; 八木 一乃大; 中野 直樹; 露口 尚弘; 奥田 武司; 湯上 春樹; 岡田 理恵子; 加藤 天美; 原 嘉信 解剖学雑誌 85 (2) 78 -78 2010年06月
- 藪内 伴成; 中西 欣弥; 寺本 佳史; 布川 知史; 中川 修宏; 眞田 寧皓; 奥田 武司; 辻 潔; 岩倉 倫裕; 加藤 天美 脳神経外科速報 20 (5) 580 -585 2010年05月
- 奥田武司; 湯上春樹; 加藤天美 日本間脳下垂体腫よう学会プログラム・抄録集 20th 142 2010年
- 奥田武司; 湯上春樹; 中野直樹; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 14th 120 2009年08月
- 奥田武司; 湯上春樹; 片岡和夫; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 14th 113 2009年08月
- 奥田 武司; 片岡 和夫; 加藤 天美 癌と化学療法 36 (4) 599 -603 2009年04月
- 奥田武司; 湯上春樹; 加藤天美 日本脳腫瘍学会プログラム・抄録集 27th 271 2009年
- 湯上春樹; 住井利寿; 奥田武司; 中村英剛; 内山卓也; 渡邊啓; 加藤天美 日本脳神経外科学会総会抄録集(CD-ROM) 68th ROMBUNNO.2P-DP070-09 2009年
- 奥田武司; 片岡和夫; 湯上春樹; 加藤天美 日本脳神経外科学会総会抄録集(CD-ROM) 68th ROMBUNNO.1K-DP004-01 2009年
- 加藤天美; 橋本直哉; 谷口理章; 藤本康倫; 吉峰俊樹; 湯上春樹; 眞田寧皓; 住井利寿; 奥田武司 日本脳神経外科学会総会抄録集(CD-ROM) 68th ROMBUNNO.2B-S12-05 2009年
- 悪性リンパ腫におけるfluorescein術中蛍光診断の有用性奥田 武司; 片岡 和夫; 加藤 天美 Neurological Surgery 36 (11) 1001 -1004 2008年11月
- 山田 公人; 奥田 武司; 薮内 伴成; 湯上 春樹; 住井 利寿; 寺本 佳史; 片岡 和夫; 加藤 天美 日本脳神経外科学会総会CD-ROM抄録集 67回 1J -03 2008年10月
- 奥田 武司; 片岡 和夫; 湯上 春樹; 住井 利寿; 山田 公人; 加藤 天美 日本脳神経外科学会総会CD-ROM抄録集 67回 1J -04 2008年10月
- 湯上 春樹; 住井 利寿; 奥田 武司; 山田 公人; 加藤 天美 日本脳神経外科学会総会CD-ROM抄録集 67回 2J -10 2008年10月
- 奥田武司; 寺本佳史; 湯上春樹; 住井利寿; 片岡和夫; 加藤天美 日本脳腫瘍の外科学会プログラム・抄録集 13th 158 2008年
- 藪内伴成; 中西欣弥; 中野直樹; 寺本佳史; 奥田武司; 渡邉啓; 加藤天美; 種子田護 大阪市医学会雑誌 56 (3-4) 118 -118 2007年12月
- 奥田 武司; 片岡 和夫; 眞島 静; 北野 昌彦; 加藤 天美 日本脳神経外科学会総会CD-ROM抄録集 66回 1K -P06 2007年10月
- 薮内 伴成; 奥田 武司; 赤井 文治; 内山 卓也; 住井 利寿; 眞島 静; 北野 昌彦; 種子田 護; 加藤 天美 日本脳神経外科学会総会CD-ROM抄録集 66回 2K -P35 2007年10月
- 不全片麻痺の原因としての頸椎特発性脊髄硬膜外血腫中西 欣弥; 中野 直樹; 寺本 佳史; 奥田 武司; 渡邉 啓; 薮内 伴成; 加藤 天美; 種子田 護 日本脳神経外科学会総会CD-ROM抄録集 66回 3K -P61 2007年10月
- 一酸化窒素刺激下における培養グリオーマ細胞のDNAマイクロアレイ解析奥田 武司; 片岡 和夫; 渡邉 啓; 種子田 護 Brain Tumor Pathology 24 (Suppl.) 82 -82 2007年04月
- 渡邉 啓; 片岡 和夫; 辻 潔; 奥田 武司; 種子田 護 近畿大学医学雑誌 32 (1) 22A 2007年03月
- 奥田 武司 近畿大学医学雑誌 31 (4) 251 -261 2006年12月
- 蝶形骨平面からの髄液漏に対する外科的治療奥田 武司; 北野 昌彦; 種子田 護 Neurological Surgery 34 (11) 1119 -1123 2006年11月
- 奥田 武司; 北野 昌彦; 眞島 静; 種子田 護 脳神経外科速報 16 (6) 565 -569 2006年06月
- 乳癌原発の多発脳転移に対する積極的治療奥田 武司; 中川 秀光; 田村 雅一; 福島 裕治; 芳村 憲泰 脳神経外科ジャーナル 14 (3) 138 -143 2005年03月
- Marfan症候群に同時発症したクモ膜下出血と急性大動脈解離の1例奥田 武司; 伊泊 広二; 新垣 安男; 沖山 光則; 當山 真人 脳神経外科ジャーナル 12 (6) 445 -447 2003年06月
- 奥田 武司; 赤井 文治; 中野 直樹 Brain and nerve : 神経研究の進歩 55 (1) 65 -69 2003年01月
- 診断困難であった難治性,結核性髄膜炎の1例奥田 武司; 赤井 文治; 中野 直樹; 内山 卓也; 種子田 護 脳と神経 55 (1) 65 -69 2003年01月
- 内山 卓也; 中野 直樹; 布川 知史; 奥田 武司; 種子田 護 Functional neurosurgery : proceedings of the annual meeting of the Japan Society for Stereotactic and Functional Neurosurgery 41 (1) 13 -18 2002年06月
- 内山 卓也; 中野 直樹; 布川 知史; 奥田 武司; 種子田 護 機能的脳神経外科 : 日本定位・機能神経外科学会機関誌 = Functional neurosurgery : official journal of the Japan Society for Stereotactic and Functional Neurosurgery 40 (2) 66 -67 2001年12月
- 山田 公人; 片岡 和夫; 奥田 武司; 布川 知史; 中西 欣弥; 種子田 護 近畿大学医学雑誌 26 (2) 2001年10月
- 奥田 武司; 北野 昌彦; 眞島 静; 渡邊 啓; 辻 潔; 中澤 憲; 湯上 春樹; 中川 修宏; 布川 知史; 中村 英剛; 中野 直樹; 内山 卓也; 朝井 俊治; 赤井 文治; 片岡 和夫; 種子 田護 近畿大学医学雑誌 25 (2) 2000年12月
- 奥田 武司; 木本 敦史; 中川 修宏; 赤井 文治; 内山 卓也; 種子田 護 近畿大学医学雑誌 24 (2) 1999年12月
書籍等出版物
- リハビリテーションテキスト:画像評価学奥田武司 (担当:分担執筆範囲:脳神経系(1) 正常像と基礎知識)中山書店 2024年08月
- 臨床脳腫瘍学奥田武司 (担当:分担執筆範囲:転移性脳腫瘍に対する手術療法)日本臨床社 2023年12月
- 高齢者がん医療Q &A奥田武司 (担当:分担執筆範囲:脳腫瘍)金原出版株式会社 2020年10月
- ペランパネルによるてんかん治療のストラテジー奥田武司 (担当:分担執筆範囲:脳腫瘍関連てんかんにおけるペランパネルによるアプローチ)先端医学社 2019年01月
- 転移性脳腫瘍 診断・治療・管理マニュアル監修; 中川和彦; 編著; 奥田武司; 中洲庸子 (担当:共編者(共編著者)範囲:転移性脳腫瘍の治療)メディカ出版 2014年12月
- 急性・重症患者ケア ICUでの脳神経看護奥田武司 (担当:分担執筆範囲:髄膜炎・脳膿瘍の診断、治療)総合医学社 2014年05月
- Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain TumorsTakeshi Okuda (担当:分担執筆範囲:Surgical Treatment for Multiple Brain Metastases)InTech 2013年04月
- Diagnostic Techniques and Surgical Management of Brain TumorsTakeshi Okuda (担当:分担執筆範囲:Surgical technique for metastatic brain tumors)InTech 2011年07月
共同研究・競争的資金等の研究課題
- 日本学術振興会:科学研究費助成事業 基盤研究(C)研究期間 : 2020年04月 -2023年03月代表者 : 奥田 武司2021 年度は肺癌血行性脳転移マウスモデルの脳組織を採取し、フローサイトメトリー法を用いてマクロファージ分画上の B7-H3 および B7-H5 発現レベルを確認した。同時に脳腫瘍組織より M2 マクロファージを単離して mRNA を抽出し、DNA マイクロアレイを用いたトランスクリプトーム解析を行った。さらにマルチプレックスサイトカイン測定も導入し、限定された臨床検体サンプルから相当量のサイトカイン/ケモカインデータの取得を行なっている。 他者の先行研究では肺癌細胞上に B7-H3 が発現することが示され、B7-H3 を標的とした治療薬が治験レベルで用いられるようになった。そこで我々真相学習アルゴリズムを用いた病理組織解析システム Cu-Cyto を用いて、腫瘍組織中の B7-H3 発現を解析した。上記知見と同様、一部の転移性肺癌細胞は B7-H3 を発現しており、かつ腫瘍組織に浸潤するマクロファージ上にも B7-H3 発現がみられた。 近年腫瘍組織近傍に三次リンパ節様構造物 (Tertiary Lymphoid Structures: TLS または Tertiary Lymphoid Organs: TLO) が形成され、腫瘍増殖あるいは腫瘍制御に関わることが示されている。そこで我々は Cu-Cyto システムを用いて上記腫瘍組織中での TLS/TLO を検索し、これらの発現頻度等を調べた。
- 日本学術振興会:科学研究費助成事業 基盤研究(C)研究期間 : 2017年04月 -2020年03月代表者 : 泉本 修一; 加藤 天美; 奥田 武司; 藤田 貢マウス担脳腫瘍(神経膠腫)モデルおよびヒト神経膠腫においてWT1ワクチン治療前後の局所での獲得性免疫動態を明らかにし、グレード2/3神経膠腫に対するWT1ワクチン治療の開発を行うことを本研究の目標としている。 Ⅰ:初年度から継続してC57BL/6マウスをモデルとして用い、( I ) 正常マウスおよび( ii ) 担脳腫瘍(203G由来)マウスを作成した。それらに対して脳組織でCD4陽性細胞、CD8陽性細胞を免疫組織学的に同定し、その集族や時間的動態を明らかにした。コントロールとして行った正常マウスに対して、担脳腫瘍マウスの脳では、限局性であったが免疫担当細胞の集族が認められ、局所獲得免疫細胞として評価した。 Ⅱ:ヒトにおいて、グレード2/3神経膠腫初回摘出時および再手術時の腫瘍組織および辺縁組織を用いて検討した。それぞれの腫瘍組織においてWT1の発現およびCD4、CD8陽性細胞を免疫組織学的に同定し、その免疫担当細胞の集族を明らかにした。全ての腫瘍細胞でWT1は発現されていたがグレード3やグレード4神経膠腫に比べ、グレード2神経膠腫に弱い傾向があった。そのなかで治療中ステロイド投与時あるいは抗けいれん剤投与時の上記免疫担当細胞の移動を検討した。 初年度から研究体制の変更を要し、実験を再構築したため満足のいくものではなかった。しかしながら免疫治療の継続実績があり初年度から治療関連で学会発表や論文投稿ができた。
- 日本学術振興会:科学研究費助成事業 基盤研究(C)研究期間 : 2015年04月 -2018年03月代表者 : 奥田 武司; 藤田 貢; 中田 晋肺がんにおける脳転移発症のメカニズムにM2マクロファージを中心とした免疫機構が関与していることが判明した。さらにマイクロアレイ解析にて、このM2マクロファージの治療標的となり得る遺伝子群も同定することができた。また、この免疫応答は腸内細菌が産生する代謝産物も関与していることを証明した。これらより、今後、脳転移を予防する新たな治療戦略が得られる可能性が示唆された。
- 日本学術振興会:科学研究費助成事業 基盤研究(C)研究期間 : 2014年04月 -2017年03月代表者 : 泉本 修一; 友金 祐介; 奥田 武司; 藤田 貢; 加藤 天美転移性脳腫瘍に対してWT1免疫療法を行う妥当性を、動物モデル研究、ヒト免疫反応の研究を通して、治療前後の細胞性免疫反応を中心に解析した。担脳腫瘍マウスモデルでは、脳腫瘍細胞のWT1発現を確認し、限局性であったが免疫担当細胞の集族を明らかにした。しかしながらWT1ペプチドに治療よる効果発現は軽度であった。ヒトにおいて、乳癌の転移性脳腫瘍に対し分子標的治療時の免疫担当細胞の動態解析を行った。腫瘍細胞表面抗原WT1の発現は軽度でありWT1特異的キラーT細胞の変化も軽度であった。しかしながらWT1ペプチドの投与局所皮下組織においてCD4およびCD8免疫担当細胞が集族していることを確認した。
- 日本学術振興会:科学研究費助成事業 若手研究(B)研究期間 : 2012年04月 -2014年03月代表者 : 藤田 貢; 義江 修; 中田 晋; 奥田 武司; 加藤 天美肺がんに対する治療成績向上に伴い転移性脳腫瘍の罹患率が増加している。近年がん増殖・浸潤・転移における免疫系の関わりが明らかとなりつつあり、NSAID の長期投与によるがん死亡率低下が報告された。近年我々は、脳腫瘍発生初期において骨髄由来抑制細胞 (MDSC) が CCL2/CXCL12 ケモカイン依存性に病変部に集積し、発症のトリガーとなり、かつ NSAID により COX-2 阻害により MDSC 抑制および脳腫瘍発生抑制しうることを示してきた。それらの知見を元に、本研究では、特に肺がん転移性脳腫瘍発症における MDSC の影響を、マウスによる非臨床研究およびヒト臨床研究の両面から評価した。
- 日本学術振興会:科学研究費助成事業 若手研究(B)研究期間 : 2005年 -2007年代表者 : 奥田 武司神経膠芽腫の摘出標本を用いた免疫染色を行った。術前にインターフェロンを静脈内投与、局所投与したものと投与なしで比較すると、局所投与した群にのみ誘導型一酸化窒素合成酵素(iNOS)の発現が認められた。このiNOSの発現細胞は二重染色の結果、脳内マクロファージであるミクログリアと判明、インターフェロンでの直接刺激によるものと考えられた。また高濃度のiNOSは大量の一酸化窒素(NO)を誘導することが判明している。次に神経膠芽腫の培養細胞を用いてNO負荷による抗腫瘍効果をDNAマイクロアレイを用いて解析した。NO負荷を与えた群と負荷なしの群で比較したところ、NO負荷では明らかな腫瘍増殖抑制関連の遺伝子が発現増加しており、また腫瘍増殖効果をもつ関連遺伝しの発現低下がみられた。これらの結果より、従来の報告ではインターフェロンの抗腫瘍効果はp53を介したものとされていたが、神経膠芽腫の場合、大量のNO誘導による新たな経路が生じている可能性がある。特に大量のNOによりEGFR-JAK/STAT経路を介している可能性が判明した。さらに培養細胞を用いてインターフェロンによる大量NO誘導療法を増強させるため、リポポリサッカライドを追加し、検討している。またEGFRの分子標的薬剤も追加し、抗腫瘍効果の増強を検討している。神経膠芽腫の新規化学療法としてアルキル化剤のTemozolomideが使用されているが、本薬剤はインターフェロンの併用によりMGMTの不活化が促進された結果、抗腫瘍効果の増強が予想される。このため、現在、全国規模で治験が行われている。これより、本研究結果も合わせてインターフェロンの静脈内投与+局所投与により、抗腫瘍効果が増強され、神経膠芽腫治療が進歩する可能性がある。